Jazz Pharma to sell women's health business for $95M

Jazz Pharmaceuticals will sell its women's heath business to specialty pharmaceutical company Meda for $95 million in cash. Jazz, which has an office in Palo Alto (NASDAQ:JAZZ) said in the release that the sale involves six products: Elestrin, Gastrocrom, Natelle One, AVC, Gesticare DHA and Urelle.